Hepatocyte growth factor gene therapy for islet transplantation

Expert Opinion on Biological Therapy

Volumn 4, Issue 4, 2004, Pages 507-518

  Rao, Poornima ^a   Cozar Castellano, Irene ^a   Roccisana, Jennifer ^a   Vasavada, Rupangi C ^a   Garda Ocaña, Adolfo ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Gene therapy; Growth factor; Hepatocyte growth factor; Islet transplantation; Pancreatic beta cell; Pancreatic islet; Transgenic mouse

Indexed keywords

ADENOVIRUS VECTOR; ANTISERUM; DACLIZUMAB; DEXTRAN SULFATE; GASTRIN; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; GROWTH FACTOR; IMMUNOSUPPRESSIVE AGENT; INSULIN; MITOGENIC AGENT; PARATHYROID HORMONE RELATED PROTEIN; PLACENTA LACTOGEN; RAPAMYCIN; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; SOMATOMEDIN B; SOMATOMEDIN C; STREPTOZOCIN; TACROLIMUS; TRANSFORMING GROWTH FACTOR ALPHA;

ALLOTRANSPLANTATION; CELL DIVISION; CELL FUNCTION; CELL PROLIFERATION; CELL PROTECTION; CELL SURVIVAL; CLINICAL PRACTICE; CYTOTOXICITY; DIABETES MELLITUS; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ENDOCRINE FUNCTION; GENE OVEREXPRESSION; GENE THERAPY; GENE TRANSFER; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; KIDNEY CAPSULE; MITOGENESIS; NONHUMAN; PANCREAS; PANCREAS FUNCTION; PANCREAS ISLET BETA CELL; PANCREAS ISLET TRANSPLANTATION; PREOPERATIVE TREATMENT; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REGULATORY MECHANISM; REVIEW; RODENT; SCID MOUSE; STREPTOZOCIN DIABETES; TRANSGENIC MOUSE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ANIMALS; GENE THERAPY; GENETIC VECTORS; HEPATOCYTE GROWTH FACTOR; ISLETS OF LANGERHANS; ISLETS OF LANGERHANS TRANSPLANTATION; MICE; MICE, TRANSGENIC;

ADENOVIRIDAE; MUS MUSCULUS; RODENTIA;

EID: 1842633502     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.4.4.507     Document Type: Review

References (67)

1. MOSKALEWSKI S: Isolation and culture of the islets of Langerhans of the guinea pig. Gen. Comp. Endocrinol. (1965) 5:342-353.
2. SUTHERLAND D, GRUESSNER R: Current status of pancreas transplantation for the treatment of type 1 diabetes. Clin. Diab. (1997) 2:152-156.
3. BECKER BN, ODORICO JS, BECKER YT et al.: Simultaneous pancreas-kidney and pancreas transplantation. J. Am. Soc. Nephrol. (2001) 12:2517-2527.
4. SHAPIRO AM, LAKEY JR, RYAN EA et al.: Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N. Engl. J. Med. (2000) 343:230-238. The Edmonton protocol and its successful application in patients with type 1 diabetes.
5. RYAN EA, LAKEY JR, RAJOTTE RV et al.: Clinical outcomes and insulin secretion after islet transplantation with the Edmonton protocol. Diabetes (2001) 50:710-719.
6. RYAN EA, LAKEY JR, PATY BW et al.: Successful islet transplantation: continued insulin reserve provides long-term glycemic control. Diabetes (2002) 51:2148-2157.
7. BRETZEL RG, HERING BJ, FEDERLIN KF: Islet cell transplantation in diabetes mellitus-from bench to bedside. Exp. Clin. Endocrinol. Diabetes (1995) 103(Suppl. 2):143-159.
8. HAYEK A, BEATTIE GM: Alternatives to unmodified human islets for transplantation. Curr. Diab. Rep. (2002) 2:371-376. Different approaches to improve islet transplantation.
9. SORENSON RL, BRELJE TC: Adaptation of islets of Langerhans to pregnancy: beta-cell growth, enhanced insulin secretion and the role of lactogenic hormones. Horm. Metab. Res. (1997) 29:301-307.
10. BONNER-WEIR S, DEERY D, LEAHY JL, WEIR GC: Compensatory growth of pancreatic beta-cells in adult rats after short-term glucose infusion. Diabetes (1989) 38:49-53.
11. HAHN VON DORSCHE H, SCHAFER H, TITLBACH M: Histophysiology of the obesity-diabetes syndrome in sand rats. Adv. Anat. Embryol. Cell Biol. (1994) 130:1-95.
12. BOUWENS L, KLOPPEL G: Islet cell neogenesis in the pancreas. Virchows Arch. (1996) 427:553-560.
13. SCAGLIA L, SMITH FE, BONNER-WEIR S: Apoptosis contributes to the involution of beta cell mass in the post partum rat pancreas. Endocrinology (1995) 136:5461-5468.
14. MIZUNO N, YOSHITOMI H, ISHIDA H et al.: Altered bcl-2 and bax expression and intracellular Ca2+ signaling in apoptosis of pancreatic cells and the impairment of glucose-induced insulin secretion. Endocrinology (1998) 139:1429-1439.
15. MATHIS D, VENCE L, BENOIST C: Beta-cell death during progression to diabetes. Nature (2001) 414:792-798.
16. DAVALLI AM, SCAGLIA L, ZANGEN DH, HOLLISTER J, BONNER-WEIR S, WEIR GC: Vulnerability of islets in the immediate posttransplantation period. Dynamic changes in structure and function. Diabetes (1996) 45:1161-1167. Reports drastic decreases in beta cell mass after islet transplantation under the kidney capsule of mice.
17. BUTLER AE, JANSON J, BONNER-WEIR S, RITZEL R, RIZZA RA, BUTLER PC: Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes (2003) 52:102-110.
18. GARCIA-OCANA A, VASAVADA RC, TAKANE KK, CEBRIAN A, LOPEZ-TALAVERA JC, STEWART AF: Using beta-cell growth factors to enhance human pancreatic Islet transplantation. J. Clin. Endocrinol. Metab. (2001) 86:984-988. Describes in vitro and in vivo actions of different growth factors in the beta cell.
19. NAKAMURA T, NAWA K, ICHIHARA A: Partial purification and characterization of hepatocyte growth factor from serum of hepatectomized rats. Biochem. Biophys. Res. Commun. (1984) 122:1450-1459.
20. FURGE KA, ZHANG YW, VANDE WOUDE GF: Met receptor tyrosine kinase: enhanced signaling through adapter proteins. Oncogene (2000) 19:5582-5589.
21. STUART KA, RIORDAN SM, LIDDER S, CROSTELLA L, WILLIAMS R, SKOUTERIS GG: Hepatocyte growth factor/scatter factor-induced intracellular signalling. Int. J. Exp. Pathol. (2000) 81:17-30.
22. KITTA K, DAY RM, IKEDA T, SUZUKI YJ: Hepatocyte growth factor protects cardiac myocytes against oxidative stress-induced apoptosis. Free Radic. Biol. Med. (2001) 31:902-910.
23. FAN S, MAO YX, WANG J-A et al.: The cytokine hepatocyte growth factor/scatter factor inhibits apoptosis and enhances DNA repair by a common mechanism involving signaling through phosphatidyl inositol 3′ kinase. Oncogene (2000) 19:2212-2223.
24. LIU Y: Hepatocyte growth factor promotes renal epithelial cell survival by dual mechanisms. Am. J. Physiol. (1999) 277:F624-F633.
25. ZHANG L, HIMI T, MORITA I, MUROTA S: Hepatocyte growth factor protects cultured rat cerebellar granule neurons from apoptosis via the phosphatidylinositol-3 kinase/Akt pathway. J. Neurosci. Res. (2000) 59:489-496.
26. KOSAI K, MATSUMOTO K, NAGATA S, TSUJIMOTO Y, NAKAMURA T: Abrogation of Fas-induced fulminant hepatic failure in mice by hepatocyte growth factor. Biochem. Biophys. Res. Commun. (1998) 244:683-690.
27. BLADT F, RIETHMACHER D, ISENMANN S, AGUZZI A, BIRCHMEIER C: Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud. Nature (1995) 376:768-771.
28. UEHARA Y, MINOWA O, MORI C et al.: Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/scatter factor. Nature (1995) 373:702-705.
29. CALVO EL, BOUCHER C, PELLETIER G, MORISSET J: Ontogeny of hepatocyte growth factor and c-met/hgf receptor in rat pancreas. Biochem. Biophys. Res. Commun. (1996) 229:257-263.
30. TSUDA H, IWASE T, MATSUMOTO K et al.: Immunohistochemical localization of hepatocyte growth factor protein in pancreas islet A-cells of man and rats. Jpn. J. Cancer Res. (1992) 83:1262-1266.
31. OTONKOSKI T, CIRULLI V, BEATTIE M et al.: A role for hepatocyte growth factor/scatter factor in fetal mesenchyme-induced pancreatic beta-cell growth. Endocrinology (1996) 137:3131-3139.
32. BULOTTA A, DI CESARE E, PONTE E et al.: Increased c-met expression during ductal beta cell neogenesis in experimental autoimmune diabetes. Growth Factors (2001) 19:259-267.
33. MENKE A, YAMAGUCHI H, GIEHL K, ADLER G: Hepatocyte growth factor and fibroblast growth factor 2 are overexpressed after cerulein-induced acute pancreatitis. Pancreas (1999) 18:28-33.
34. WARZECHA Z, DEMBINSKI A, KONTUREK PC et al.: Hepatocyte growth factor attenuates pancreatic damage in caerulein-induced pancreatitis in rats. Eur. J. Pharmacol. (2001) 430:113-121.
35. BEATTIE GM, RUBIN JS, MALLY MI, OTONKOSKI T, HAYEK A: Regulation of proliferation and differentiation of human fetal pancreatic islet cells by extracellular matrix, hepatocyte growth factor, and cell-cell contact. Diabetes (1996) 45:1223-1228.
36. HAYEK A, BEATTIE GM, CIRULLI V, LOPEZ AD, RICORDI C, RUBIN JS: Growth factor/matrix-induced proliferation of human adult beta-cells. Diabetes (1995) 44:1458-1460. First study describing the mitogenic effects of HGF in the adult human beta cell.
37. OTONKOSKI T, BEATTIE GM, RUBIN JS, LOPEZ AD, BAIRD A. HAYEK A: Hepatocyte growth factor/scatter factor has insulinotropic activity in human fetal pancreatic cells. Diabetes (1994) 43:947-953. First study describing the mitogenic effects of HGF in the fetal human beta cell.
38. OTONKOSKI T, MALLY MI, HAYEK A: Opposite effects of beta-cell differentiation and growth on reg expression in human fetal pancreatic cells. Diabetes (1994) 43:1164-1166.
39. GAHR S, MERGER M, BOLLHEIMER LC, HAMMERSCHMIED CG, SCHOLMERICH J, HUGL SR: Hepatocyte growth factor stimulates proliferation of pancreatic beta-cells particularly in the presence of subphysiological glucose concentrations. J. Mol. Endocrinol. (2002) 28:99-110.
40. BOUWENS L, LU WG, DE KRIJGER R: Proliferation and differentiation in the human fetal endocrine pancreas. Diabetologia (1997) 40:398-404.
41. HALBAN PA, PRAZ GZ, WOLLHEIM CB: Abnormal glucose metabolism accompanies failure of glucose to stimulate release from a rat pancreatic cell line (RINm5F). Biochem. J. (1983) 212:439-443.
42. BEATTIE GM, MONTGOMERY AM, LOPEZ AD et al.: A novel approach to increase human islet cell mass while preserving beta-cell function. Diabetes (2002) 51:3435-3439. Describes how HGF can be used to expand human beta cells in vitro while preserving their function.
43. MASHIMA H, SHIBATA H, MINE T, KOJIMA I: Formation of insulin-producing cells from pancreatic acinar AR42J cells by hepatocyte growth factor. Endocrinology (1996) 137:3969-3976.
44. GARCIA-OCANA A, TAKANE KK, REDDY VT, LOPEZ-TALAVERA J-C, VASAVADA RC, STEWART AF: Adenovirus-mediated hepatocyte growth factor expression in mouse islets improves pancreatic islet transplant performance and reduces beta cell death. J. Biol. Chem. (2003) 278:343-351. First study describing the use of gene therapy with HGF gene to improve islet transplant performance in mice.
45. GARCIA-OCANA A, TAKANE KK, SYED MA, PHILBRICK WM, VASAVADA RC, STEWART AF: Hepatocyte growth factor overexpression in the islet of transgenic mice increases beta cell proliferation, enhances islet mass, and induces mild hypoglycemia. J. Biol. Chem. (2000) 275:1226-1232. First study describing the in vivo effects of HGF overexpression in the pancreatic beta cell of transgenic mice.
46. SCAGLIA L, CAHILL CJ, FINEGOOD DT, BONNER-WEIR S: Apoptosis participates in the remodeling of the endocrine pancreas in the neonatal rat. Endocrinology (1997) 138:1736-1741.
47. XIAO GH, JEFFERS M, BELLACOSA A, MITSUUCHI Y, VANDE WOUDE GF, TESTA JR: Anti-apoptotic signaling by hepatocyte growth factor/Met via the phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase pathways. Proc. Natl. Acad. Sci. USA (2001) 98:247-252.
48. SUZUKI A, HAYASHIDA M, KAWANO H, SUGIMOTO K, NAKANO T, SHIRAKI K: Hepatocyte growth factor promotes cell survival from fas-mediated cell death in hepatocellular carcinoma cells via Akt activation and Fas-death-inducing signaling complex suppression. Hepatology (2000) 32:796-802.
49. DAI C, LI Y, YANG J, LIU Y: Hepatocyte growth factor preserves beta cell mass and mitigates hyperglycemia in streptozotocin-induced diabetic mice. J. Biol. Chem. (2003) 278:27080-27087.
50. GARCIA-OCANA A, VASAVADA R C, CEBRIAN A et al.: Transgenic overexpression of hepatocyte growth factor in the beta-cell markedly improves islet function and islet transplant outcomes in mice. Diabetes (2001) 50:2752-2762. Study indicating the potential of HGF overexpression in the beta cell as a therapeutic strategy for improving islet transplant performance.
51. HALVORSEN TL, BEATTIE GM, LOPEZ AD, HAYEK A, LEVINE F: Accelerated telomere shortening and senescence in human pancreatic islet cells stimulated to divide in vitro. J. Endocrinol. (2000) 166:103-109.
52. DAVALLI AM, OGAWA Y, RICORDI C, SCHARP DW, BONNER-WEIR S, WEIR GC: A selective decrease in the beta cell mass of human islets transplanted into diabetic nude mice. Transplantation (1995) 59:817-820.
53. CONTRERAS JL, ECKHOFF DE, CARTNER S et al.: Long-term functional islet mass and metabolic function after xenoislet transplantation in primates. Transplantation (2000) 69:195-201.
54. PILEGGI A, RICORDI C, ALESSIANI M, INVERARDI L: Factors influencing Islet of Langerhans graft function and monitoring. Clin. Chim. Acta (2001) 310:3-16.
55. MELLERT J, HERING BJ, LIU X et al.: Critical islet mass for successful porcine islet autotransplantation. J. Mol. Med. (1999) 77:126-129.
56. NAKANO M, YASUNAMI Y, MAKI T et al.: Hepatocyte growth factor is essential for amelioration of hyperglycemia in streptozotocin-induced diabetic mice receiving a marginal mass of intrahepatic islet grafts. Transplantation (2000) 69:214-221. First study describing the use of in vivo administration of HGF and dextran sulfate to improve islet transplantation in rodents.
57. ZIONCHECK TF, RICHARDSON L, LIU J et al.: Sulfated oligosaccharides promote hepatocyte growth factor association and govern its mitogenic activity. J. Biol. Chem. (1995) 270:16871-16878.
58. ZIONCHECK TF, RICHARDSON L, DEGUZMAN GG, MODI NB, HANSEN SE, GODOWSKI PJ: The pharmacokinetics, tissue localization, and metabolic processing of recombinant human hepatocyte growth factor after intravenous administration in rats. Endocrinology (1994) 134:1879-1887.
59. ROOS F, RYAN AM, CHAMOW SM, BENNETT GL, SCHWALL RH: Induction of liver growth in normal mice by infusion of hepatocyte growth factor/scatter factor. Am. J. Physiol. (1995) 268:G380-G386.
60. TAKAYAMA H, LAROCHELLE WJ, SHARP R et al.: Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor. Proc. Natl. Acad. Sci. USA (1997) 94:701-706.
61. TAKAYAMA H, LAROCHELLE WJ, ABNIS SG, OTSUKA T, MERLINO G: Renal tubular hyperplasia, polycystic disease, and glomerulosclerosis in transgenic mice overexpressing hepatocyte growth factor/scatter factor. Lab. Invest. (1997) 77:131-138.
62. BECKER TC, NOEL RJ, COATS WS et al.: Use of recombinant adenovirus for metabolic engineering of mammalian cells. Methods Cell. Biol. (1994) 43:161-189.
63. WEBER M, DENG S, KUCHER T, SHAKED A, KETCHUM RJ, BRAYMAN KL: Adenoviral transfection of isolated pancreatic islets: a study of programmed cell death (apoptosis) and islet function. J. Surg. Res. (1997) 69:23-32.
64. LEIBOWITZ G, BEATTIE GM, KAFRI T et al.: Gene transfer to human pancreatic endocrine cells using viral vectors. Diabetes (1999) 48:745-753.
65. MURUVE DA, MANFRO RC, STROM TB, LIBERMANN TA: Ex vivo adenovirus-mediated gene delivery leads to long-term expression in pancreatic islet transplants. Transplantation (1997) 64:542-546.
66. LOPEZ-TALAVERA JC, GARCIA-OCANA A, SIPULA I et al.: Hepatocyte growth factor gene therapy for pancreatic islets in diabetes: reducing the minimal islet transplant mass required in a glucocorticoid-free rat model of allogeneic portal vein islet transplantation. Endocrinology (2004) 145:467-474. Study describing the usefulness of gene therapy with HGF gene to improve islet allograft performance in rats treated with the immunosuppressive regime used in the Edmonton protocol.
67. ZENG Y, RICORDI C, LENDOIRE J et al.: The effect of prednisone on pancreatic islet autografts in dogs. Surgery (1993) 113:98-102.